Panzade Prabhakar, Shendarkar Giridhar
Center for Research in Pharmaceutical Sciences, Nanded Pharmacy College, Opp. Kasturba Matruseva Kendra, Sham Nagar, Nanded, India.
Turk J Pharm Sci. 2019 Sep;16(3):310-316. doi: 10.4274/tjps.galenos.2018.15013. Epub 2019 Jul 10.
Pharmaceutical cocrystals are a promising tool to enhance the solubility and dissolution of poorly soluble drugs. Zaltoprofen (ZFN) is nonsteroidal anti-inflammatory drug with a prevalent solubility problem. The present study was undertaken to enhance the solubility and dissolution of ZFN through pharmaceutical cocrystals by screening various coformers.
Cocrystals of ZFN were prepared in 1:1 and 1:2 ratio of drug:coformer by the dry grinding method. The melting point and solubility of the crystalline phase were determined. The potential cocrystals were characterized by differential scanning calorimetry (DSC), infrared spectroscopy, and powder X-ray diffraction (PXRD). Cocrystals were subjected to dissolution rate and stability study.
ZFN-nicotinamide (NIC) cocrystals demonstrated deviation in melting point and solubility. The cocrystals were obtained in both 1:1 and 1:2 ratios with NIC. The infrared analysis noticeably indicated the shifting of characteristic bands of ZFN. The crystallinity of the cocrystals was evident from the XRPD pattern and notable difference in the 2θ values of intense peaks. The DSC spectra of the cocrystals exhibited altered endotherms analogous to melting point. The cocrystals showed a faster dissolution rate and a 55% increase in the extent of dissolution compared to pure drug. The cocrystals were stable at room temperature and accelerated conditions.
The prepared cocrystals exhibited greater solubility and dissolution compared to the pure drug and were stable at room temperature and accelerated conditions.
药物共晶是提高难溶性药物溶解度和溶出度的一种有前景的工具。扎托洛芬(ZFN)是一种存在普遍溶解度问题的非甾体抗炎药。本研究旨在通过筛选各种共形成物,利用药物共晶提高ZFN的溶解度和溶出度。
采用干磨法以药物:共形成物1:1和1:2比例制备ZFN的共晶。测定结晶相的熔点和溶解度。通过差示扫描量热法(DSC)、红外光谱和粉末X射线衍射(PXRD)对潜在的共晶进行表征。对共晶进行溶出速率和稳定性研究。
ZFN-烟酰胺(NIC)共晶在熔点和溶解度上表现出偏差。与NIC以1:1和1:2比例均获得了共晶。红外分析明显显示了ZFN特征峰的位移。从XRPD图谱可明显看出共晶的结晶度,且强峰的2θ值有显著差异。共晶的DSC谱显示出类似于熔点的改变的吸热峰。与纯药物相比,共晶显示出更快的溶出速率,溶出度提高了55%。共晶在室温及加速条件下均稳定。
制备的共晶与纯药物相比表现出更高的溶解度和溶出度,且在室温及加速条件下均稳定。